Revised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk

Dow Jones

Apr 14

0031 GMT - The bar for Monash IVF's board to reject a revised offer from Genesis Capital Investment and Washington H. Soul Pattinson is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. "Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders," Morgans says.(david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

April 13, 2026 20:31 ET (00:31 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2627446275"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627446275\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627446275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 08:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627446275","market":"sg","top_or_hot":-1,"title":"Revised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0031 GMT - The bar for <a href=\"https://laohu8.com/S/MNIVF\">Monash IVF</a>'s board to reject a revised offer from Genesis Capital Investment and <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a> is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.(david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 13, 2026 20:31 ET (00:31 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-14 08:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0031 GMT - The bar for <a href=\"https://laohu8.com/S/MNIVF\">Monash IVF</a>'s board to reject a revised offer from Genesis Capital Investment and <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a> is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.(david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 13, 2026 20:31 ET (00:31 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7105","symbol_name":"多领域控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627446275","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627446275","pubTimestamp":1776126660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0031 GMT - The bar for Monash IVF's board to reject a revised offer from Genesis Capital Investment and Washington H. Soul Pattinson is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7105":"多领域控股","MVF.AU":"MONASH IVF GROUP LTD","IVF":"INVO Fertility, Inc","BK7113":"保健护理机构","BK4082":"医疗保健设备","SOL.AU":"WASHINGTON H. SOUL PATTINSON","BK7508":"医药生物股","BK7083":"煤与消费用燃料"},"translate_title":"莫纳什IVF的修订出价可能会吸引股东——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MVF.AU":0.9,"SOL.AU":0.9,"IVF":1.5},"content_text":"0031 GMT - The bar for Monash IVF's board to reject a revised offer from Genesis Capital Investment and Washington H. Soul Pattinson is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.(david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 20:31 ET (00:31 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}